Imeik Technology Development Co (300896) - Total Liabilities
Based on the latest financial reports, Imeik Technology Development Co (300896) has total liabilities worth CN¥743.43 Million CNY (≈ $108.79 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Imeik Technology Development Co generate cash to assess how effectively this company generates cash.
Imeik Technology Development Co - Total Liabilities Trend (2014–2025)
This chart illustrates how Imeik Technology Development Co's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Imeik Technology Development Co to evaluate the company's liquid asset resilience ratio.
Imeik Technology Development Co Competitors by Total Liabilities
The table below lists competitors of Imeik Technology Development Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lagercrantz Group AB (publ)
ST:LAGR-B
|
Sweden | Skr8.52 Billion |
|
ShenZhen YUTO Packaging Technology Co Ltd
SHE:002831
|
China | CN¥10.67 Billion |
|
OHB SE
XETRA:OHB
|
Germany | €1.12 Billion |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
USA | $56.25 Million |
|
Big Shopping Centers Ltd
TA:BIG
|
Israel | ILA29.16 Billion |
|
COSCO SHIPPING Holdings Co. Ltd
F:C6G
|
Germany | €215.60 Billion |
|
Macy’s Inc
NYSE:M
|
USA | $11.38 Billion |
|
SIGMASTAR TECH LTD
SHE:301536
|
China | CN¥1.53 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Imeik Technology Development Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Imeik Technology Development Co stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imeik Technology Development Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imeik Technology Development Co (2014–2025)
The table below shows the annual total liabilities of Imeik Technology Development Co from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥743.43 Million ≈ $108.79 Million |
+90.44% |
| 2024-12-31 | CN¥390.37 Million ≈ $57.12 Million |
+6.27% |
| 2023-12-31 | CN¥367.32 Million ≈ $53.75 Million |
+17.44% |
| 2022-12-31 | CN¥312.77 Million ≈ $45.77 Million |
+29.08% |
| 2021-12-31 | CN¥242.31 Million ≈ $35.46 Million |
+72.53% |
| 2020-12-31 | CN¥140.45 Million ≈ $20.55 Million |
+73.51% |
| 2019-12-31 | CN¥80.95 Million ≈ $11.84 Million |
+37.51% |
| 2018-12-31 | CN¥58.87 Million ≈ $8.61 Million |
-13.55% |
| 2017-12-31 | CN¥68.09 Million ≈ $9.96 Million |
+40.80% |
| 2016-12-31 | CN¥48.36 Million ≈ $7.08 Million |
+130.51% |
| 2015-12-31 | CN¥20.98 Million ≈ $3.07 Million |
+21.76% |
| 2014-12-31 | CN¥17.23 Million ≈ $2.52 Million |
-- |
About Imeik Technology Development Co
Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate compos… Read more